Key facts
- This page summarizes Phillip A. Sharp's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Feb 2022, 15:04.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 30,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.
Footnote F2
Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.